| Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 113.42 mm | 113.42 mm | 113.42 mm | 113.42 mm | 113.42 mm | 113.42 mm |
| Cash burn (monthly) | (no burn) | (no burn) | 12.34 mm | 9.54 mm | 7.93 mm | 9.11 mm |
| Cash used (since last report) | n/a | n/a | 52.56 mm | 40.63 mm | 33.78 mm | 38.81 mm |
| Cash remaining | n/a | n/a | 60.85 mm | 72.78 mm | 79.64 mm | 74.61 mm |
| Runway (months of cash) | n/a | n/a | 4.9 | 7.6 | 10.0 | 8.2 |
| 13F holders | Current |
|---|---|
| Total holders | 83 |
| Opened positions | 22 |
| Closed positions | 12 |
| Increased positions | 37 |
| Reduced positions | 7 |
| 13F shares | Current |
|---|---|
| Total value | 79.08 bn |
| Total shares | 46.07 mm |
| Total puts | 45.60 k |
| Total calls | 41.50 k |
| Total put/call ratio | 1.1 |
| Largest owners | Shares | Value |
|---|---|---|
| Biotechnology Value Fund L P | 4.28 mm | $16.01 mm |
| 1Globe Capital | 4.20 mm | $14.12 mm |
| D. E. Shaw & Co | 4.04 mm | $13.57 mm |
| Soleus Private Equity Fund III | 3.99 mm | $14.94 mm |
| Nantahala Capital Management | 3.73 mm | $11.16 bn |
| Orbimed Advisors | 2.86 mm | $8.56 bn |
| Soleus Capital Management | 2.83 mm | $8.46 bn |
| BlackRock | 2.23 mm | $6.68 bn |
| Vanguard | 1.93 mm | $5.77 bn |
| Alyeska Investment | 1.86 mm | $5.56 bn |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 4 Feb 25 | Paterson Dan | Common Stock | Sell | Dispose S | No | No | 5.7 | 858 | 4.89 k | 346,723 |
| 13 Jan 25 | Paterson Dan | Common Stock | Sell | Dispose S | No | No | 5.24 | 8,568 | 44.90 k | 347,581 |
| 10 Jan 25 | Daniel Calkins | Common Stock | Grant | Acquire A | No | No | 0 | 38,800 | 0.00 | 86,439 |
| 10 Jan 25 | Paterson Dan | Common Stock | Grant | Acquire A | No | No | 0 | 25,000 | 0.00 | 356,149 |
| 10 Jan 25 | Paterson Dan | Common Stock | Grant | Acquire A | No | No | 0 | 100,000 | 0.00 | 331,149 |
| 6 Jan 25 | Daniel Calkins | Common Stock | Sell | Dispose S | No | No | 6.94 | 6 | 41.64 | 47,639 |
